Efficacy of cabozantinib and sunitinib for the treatment of intermediate/poor risk renal cell carcinoma based upon UK real-world data

Background: The purpose of this study was to explore the effectiveness of cabozantinib versus sunitinib for the treatment of first-line metastatic renal cell carcinoma in intermediate/poor risk patients. Materials and methods: Retrospective review of cases between 1 January 2018 and 30 June 2021 acr...

Full description

Saved in:
Bibliographic Details
Main Authors: D. Lee, G.J. Melendez-Torres, A. Challapalli, R. Frazer, J. McGrane, A. Bahl
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:ESMO Real World Data and Digital Oncology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2949820124000651
Tags: Add Tag
No Tags, Be the first to tag this record!